


1/11

Figure 1:



2/11

Figure 2:




Figure 3:

Figure 1
National Cancer Institute Developmental Therapeutics Program
Dose Response Curves

NSC D. 755027 / 1
Report Date: July 25, 2011
SSPL 0Y6C
EXP. ID: 110SR552
Test Date: May 23, 2011

Leukemia

Log₁₀ of Sample Concentration (Molar)

Percentage Growth

Cell Lines: CCF-CEM, MOL-T4, HL-60(TB), RPMI-8226, K-562, SR

Non-Small Cell Lung Cancer

Log₁₀ of Sample Concentration (Molar)

Percentage Growth

Cell Lines: A549ATCC, HOP-92, NCH-122, NCH-123, NCH-124, HOP-82, NCH-125, NCH-126, NCH-127

Colon Cancer

Log₁₀ of Sample Concentration (Molar)

Percentage Growth

Cell Lines: COLO 205, HT29, HCT-116, KM12, HCC-598, HT29

CNS Cancer

Log₁₀ of Sample Concentration (Molar)

Percentage Growth

Cell Lines: SF-298, SF-265, SNB-19, SNB-75, SF-538, U251

Melanoma

Log₁₀ of Sample Concentration (Molar)

Percentage Growth

Cell Lines: LOX IMV, M14, M14-2, SK-MEL-2, SK-MEL-28, SK-MEL-29, SK-MEL-35, SK-MEL-36, SK-MEL-37, SK-MEL-38, SK-MEL-39, SK-MEL-40, SK-MEL-41, SK-MEL-42, SK-MEL-43, SK-MEL-44, SK-MEL-45, SK-MEL-46, SK-MEL-47, SK-MEL-48, SK-MEL-49, SK-MEL-50, SK-MEL-51, SK-MEL-52, SK-MEL-53, SK-MEL-54, SK-MEL-55, SK-MEL-56, SK-MEL-57, SK-MEL-58, SK-MEL-59, SK-MEL-60, SK-MEL-61, SK-MEL-62, SK-MEL-63, SK-MEL-64, SK-MEL-65, SK-MEL-66, SK-MEL-67, SK-MEL-68, SK-MEL-69, SK-MEL-70, SK-MEL-71, SK-MEL-72, SK-MEL-73, SK-MEL-74, SK-MEL-75, SK-MEL-76, SK-MEL-77, SK-MEL-78, SK-MEL-79, SK-MEL-80, SK-MEL-81, SK-MEL-82, SK-MEL-83, SK-MEL-84, SK-MEL-85, SK-MEL-86, SK-MEL-87, SK-MEL-88, SK-MEL-89, SK-MEL-90, SK-MEL-91, SK-MEL-92, SK-MEL-93, SK-MEL-94, SK-MEL-95, SK-MEL-96, SK-MEL-97, SK-MEL-98, SK-MEL-99, SK-MEL-100

Ovarian Cancer

Log₁₀ of Sample Concentration (Molar)

Percentage Growth

Cell Lines: IOBCV1, OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-6, OVCAR-7, OVCAR-8, OVCAR-9, OVCAR-10, OVCAR-11, OVCAR-12, OVCAR-13, OVCAR-14, OVCAR-15, OVCAR-16, OVCAR-17, OVCAR-18, OVCAR-19, OVCAR-20, OVCAR-21, OVCAR-22, OVCAR-23, OVCAR-24, OVCAR-25, OVCAR-26, OVCAR-27, OVCAR-28, OVCAR-29, OVCAR-30, OVCAR-31, OVCAR-32, OVCAR-33, OVCAR-34, OVCAR-35, OVCAR-36, OVCAR-37, OVCAR-38, OVCAR-39, OVCAR-40, OVCAR-41, OVCAR-42, OVCAR-43, OVCAR-44, OVCAR-45, OVCAR-46, OVCAR-47, OVCAR-48, OVCAR-49, OVCAR-50, OVCAR-51, OVCAR-52, OVCAR-53, OVCAR-54, OVCAR-55, OVCAR-56, OVCAR-57, OVCAR-58, OVCAR-59, OVCAR-60, OVCAR-61, OVCAR-62, OVCAR-63, OVCAR-64, OVCAR-65, OVCAR-66, OVCAR-67, OVCAR-68, OVCAR-69, OVCAR-70, OVCAR-71, OVCAR-72, OVCAR-73, OVCAR-74, OVCAR-75, OVCAR-76, OVCAR-77, OVCAR-78, OVCAR-79, OVCAR-80, OVCAR-81, OVCAR-82, OVCAR-83, OVCAR-84, OVCAR-85, OVCAR-86, OVCAR-87, OVCAR-88, OVCAR-89, OVCAR-90, OVCAR-91, OVCAR-92, OVCAR-93, OVCAR-94, OVCAR-95, OVCAR-96, OVCAR-97, OVCAR-98, OVCAR-99, OVCAR-100

Breast Cancer

Log₁₀ of Sample Concentration (Molar)

Percentage Growth

Cell Lines: MCF7, BT-20, BT-549, MDA-MB-231, MDA-MB-468, MDA-MB-453, MDA-MB-436, MDA-MB-435, MDA-MB-434, MDA-MB-433, MDA-MB-432, MDA-MB-431, MDA-MB-430, MDA-MB-429, MDA-MB-428, MDA-MB-427, MDA-MB-426, MDA-MB-425, MDA-MB-424, MDA-MB-423, MDA-MB-422, MDA-MB-421, MDA-MB-420, MDA-MB-419, MDA-MB-418, MDA-MB-417, MDA-MB-416, MDA-MB-415, MDA-MB-414, MDA-MB-413, MDA-MB-412, MDA-MB-411, MDA-MB-410, MDA-MB-409, MDA-MB-408, MDA-MB-407, MDA-MB-406, MDA-MB-405, MDA-MB-404, MDA-MB-403, MDA-MB-402, MDA-MB-401, MDA-MB-400, MDA-MB-399, MDA-MB-398, MDA-MB-397, MDA-MB-396, MDA-MB-395, MDA-MB-394, MDA-MB-393, MDA-MB-392, MDA-MB-391, MDA-MB-390, MDA-MB-389, MDA-MB-388, MDA-MB-387, MDA-MB-386, MDA-MB-385, MDA-MB-384, MDA-MB-383, MDA-MB-382, MDA-MB-381, MDA-MB-380, MDA-MB-379, MDA-MB-378, MDA-MB-377, MDA-MB-376, MDA-MB-375, MDA-MB-374, MDA-MB-373, MDA-MB-372, MDA-MB-371, MDA-MB-370, MDA-MB-369, MDA-MB-368, MDA-MB-367, MDA-MB-366, MDA-MB-365, MDA-MB-364, MDA-MB-363, MDA-MB-362, MDA-MB-361, MDA-MB-360, MDA-MB-359, MDA-MB-358, MDA-MB-357, MDA-MB-356, MDA-MB-355, MDA-MB-354, MDA-MB-353, MDA-MB-352, MDA-MB-351, MDA-MB-350, MDA-MB-349, MDA-MB-348, MDA-MB-347, MDA-MB-346, MDA-MB-345, MDA-MB-344, MDA-MB-343, MDA-MB-342, MDA-MB-341, MDA-MB-340, MDA-MB-339, MDA-MB-338, MDA-MB-337, MDA-MB-336, MDA-MB-335, MDA-MB-334, MDA-MB-333, MDA-MB-332, MDA-MB-331, MDA-MB-330, MDA-MB-329, MDA-MB-328, MDA-MB-327, MDA-MB-326, MDA-MB-325, MDA-MB-324, MDA-MB-323, MDA-MB-322, MDA-MB-321, MDA-MB-320, MDA-MB-319, MDA-MB-318, MDA-MB-317, MDA-MB-316, MDA-MB-315, MDA-MB-314, MDA-MB-313, MDA-MB-312, MDA-MB-311, MDA-MB-310, MDA-MB-309, MDA-MB-308, MDA-MB-307, MDA-MB-306, MDA-MB-305, MDA-MB-304, MDA-MB-303, MDA-MB-302, MDA-MB-301, MDA-MB-300, MDA-MB-299, MDA-MB-298, MDA-MB-297, MDA-MB-296, MDA-MB-295, MDA-MB-294, MDA-MB-293, MDA-MB-292, MDA-MB-291, MDA-MB-290, MDA-MB-289, MDA-MB-288, MDA-MB-287, MDA-MB-286, MDA-MB-285, MDA-MB-284, MDA-MB-283, MDA-MB-282, MDA-MB-281, MDA-MB-280, MDA-MB-279, MDA-MB-278, MDA-MB-277, MDA-MB-276, MDA-MB-275, MDA-MB-274, MDA-MB-273, MDA-MB-272, MDA-MB-271, MDA-MB-270, MDA-MB-269, MDA-MB-268, MDA-MB-267, MDA-MB-266, MDA-MB-265, MDA-MB-264, MDA-MB-263, MDA-MB-262, MDA-MB-261, MDA-MB-260, MDA-MB-259, MDA-MB-258, MDA-MB-257, MDA-MB-256, MDA-MB-255, MDA-MB-254, MDA-MB-253, MDA-MB-252, MDA-MB-251, MDA-MB-250, MDA-MB-249, MDA-MB-248, MDA-MB-247, MDA-MB-246, MDA-MB-245, MDA-MB-244, MDA-MB-243, MDA-MB-242, MDA-MB-241, MDA-MB-240, MDA-MB-239, MDA-MB-238, MDA-MB-237, MDA-MB-236, MDA-MB-235, MDA-MB-234, MDA-MB-233, MDA-MB-232, MDA-MB-231, MDA-MB-230, MDA-MB-229, MDA-MB-228, MDA-MB-227, MDA-MB-226, MDA-MB-225, MDA-MB-224, MDA-MB-223, MDA-MB-222, MDA-MB-221, MDA-MB-220, MDA-MB-219, MDA-MB-218, MDA-MB-217, MDA-MB-216, MDA-MB-215, MDA-MB-214, MDA-MB-213, MDA-MB-212, MDA-MB-211, MDA-MB-210, MDA-MB-209, MDA-MB-208, MDA-MB-207, MDA-MB-206, MDA-MB-205, MDA

Figure 4:

**National Cancer Institute Developmental Therapeutics Program
Dose Response Curves**

Dose Response Curves


NSC: D-755828 / 1

Report Date: July 25, 2011

SSPL: 0Y8C

Test Date: May 23, 2011

EXP. ID: 1105RSS2



5/11

Figure 5:

Leukemia

Percentage Growth

Log₁₀ of Sample Concentration (Molar)

OCF-CBM, HL-60, RBC-623, K-562, SF

CNS Cancer

Percentage Growth

Log₁₀ of Sample Concentration (Molar)

SF-298, SF-295, SF-79, U87

Renal Cancer

Percentage Growth

Log₁₀ of Sample Concentration (Molar)

TK-10, CMC-1, RFX-393, A68, SK-N-SH, SK-N-BE

Prostate Cancer

Percentage Growth

Log₁₀ of Sample Concentration (Molar)

PC-3, DU-145

Melanoma

Percentage Growth

Log₁₀ of Sample Concentration (Molar)

LOX IMVI, MALME-3M, SK-MEL-28, SK-MEL-3, SK-MEL-27, SK-MEL-42

Non-Small Cell Lung Cancer

Percentage Growth

Log₁₀ of Sample Concentration (Molar)

A549, H1975, HOP-87, EKV, NCI-H23, NCI-H460, NCI-H522

Colon Cancer

Percentage Growth

Log₁₀ of Sample Concentration (Molar)

COLO-205, HCT-15, HCT-116, HCT-2998, HT29, SW-620

Ovarian Cancer

Percentage Growth

Log₁₀ of Sample Concentration (Molar)

IGROV, OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, NCI/ADR-RES


Breast Cancer

Percentage Growth

Log₁₀ of Sample Concentration (Molar)

MCF7, T-47D, MDA-MB-231, MDA-MB-468, HS-578T

6/11



7/11




Figure 8:

National Cancer Institute Developmental Therapeutics Program
Dose Response Curves

NSC: D - 75583211
Report Date: April 10, 2011

SSPL: 0Y6C	EXC
------------	-----

Test Date: February 14, 2011

P, ID: 1102NS99




Figure 9:

**National Cancer Institute Developmental Therapeutics Program
Dose Response Curves**

Dose Response Curves


NSC: D - 755833 / 1

Report Date: April 10, 2011

SSPL: 0Y8C

Test Date: February 14, 2011

D: 1102NS99



10/11




Figure 10.

Figure 11.

